Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are established effective therapies in patients with ALK-rearranged advanced non-small-cell lung cancer (NSCLC). Upon progressive disease, patients normally receive a subsequent ALK TKI. However, when disease progression occurs in a...

Descripción completa

Detalles Bibliográficos
Autores principales: König, David, Meier, Urs R., Klaeser, Bernd, Savic, Spasenija, Pless, Miklos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383154/
https://www.ncbi.nlm.nih.gov/pubmed/32774266
http://dx.doi.org/10.1159/000507850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383154/
https://www.ncbi.nlm.nih.gov/pubmed/32774266
http://dx.doi.org/10.1159/000507850

Ejemplares similares